⌘K
Loading ticker…
As of 2026-08-24, Tarsus Pharmaceuticals, Inc. Common Stock (TARS) has a 3-month relative strength percentile of 77 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 53. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.7%, relative volume 0.57×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
TARS is in a stage 1 base, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 14.5% / 6.3%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
TARS is held by 23 ETFs as of May 2026. Top owner: VTWO at 0.07% weight, $12M notional. Top 3 carry $29M.
Held by 60 ETFs · $322M across latest filings · largest weight 2.49% (PJP).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.07% | $12M | −0.03 pp |
| SCHASchwab U.S. Small-Cap ETF | 0.05% | $11M | −0.02 pp |
| VHTVanguard Health Care ETF | 0.03% | $6M | — |
| SBIO | 1.61% | $3M | −0.46 pp |
| VTWG | 0.13% | $2M | −0.06 pp |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.00% |
| $1M |
| — |
| GSSC | 0.12% | $1M | −0.07 pp |
| ESML | 0.04% | $1M | — |
| ONEQ | 0.01% | $810K | — |
| VFMO | 0.02% | $368K | −0.01 pp |
Showing 10 of 23 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | TARS Jan avg: 4.48% median: 2.30% win: 50% σ: 23.27% n: 4 2022-04-12 → 2026-07-31 | TARS Feb avg: 9.59% median: 7.65% win: 50% σ: 24.82% n: 4 2022-04-12 → 2026-07-31 | TARS Mar avg: -3.84% median: -6.00% win: 25% σ: 14.27% n: 4 2022-04-12 → 2026-07-31 | TARS Apr avg: -0.37% median: 1.05% win: 60% σ: 12.47% n: 5 2022-04-12 → 2026-07-31 | TARS May avg: -6.33% median: -6.62% win: 40% σ: 15.29% n: 5 2022-04-12 → 2026-07-31 | TARS Jun avg: -0.64% median: 5.96% win: 60% σ: 10.88% n: 5 2022-04-12 → 2026-07-31 | TARS Jul avg: 0.74% median: -4.17% win: 40% σ: 12.75% n: 5 2022-04-12 → 2026-07-31 | TARS Aug avg: 11.12% median: 7.00% win: 75% σ: 29.75% n: 4 2022-04-12 → 2026-07-31 (current) | TARS Sep avg: 8.89% median: 6.40% win: 100% σ: 9.50% n: 4 2022-04-12 → 2026-07-31 | TARS Oct avg: 9.70% median: 11.69% win: 75% σ: 22.87% n: 4 2022-04-12 → 2026-07-31 | TARS Nov avg: 10.36% median: 16.14% win: 75% σ: 12.76% n: 4 2022-04-12 → 2026-07-31 | TARS Dec avg: 4.42% median: 3.98% win: 75% σ: 14.48% n: 4 2022-04-12 → 2026-07-31 |